Diagnosis of Antiphospholipid Syndrome and Role in Different Clinical Conditions

Antiphospholipid Syndrome (APS), also referred to as Antiphospholipid Antibody Syndrome (APLA), is an autoimmune prothrombotic condition characterized by a sustained presence of antiphospholipid antibodies (aPL). These autoantibodies target proteins that bind to phospholipids on cell membranes and promote a prothrombotic or hypercoagulable state. As a result, affected individuals are at increased risk for both arterial and venous thrombotic events, in addition to pregnancy-related complications. APS may present as a primary condition or develop secondary to other autoimmune diseases, most commonly in association with systemic lupus erythematosus (SLE). The underlying pathogenesis involves antibody-mediated disruption of normal endothelial and anticoagulant mechanisms, resulting in enhanced thrombin generation and vascular thrombosis. Clinically, APS demonstrates considerable heterogeneity. Patients may present with recurrent pregnancy loss, deep vein thrombosis, pulmonary embolism, ischemic stroke, or other thrombotic manifestations affecting various vascular beds. Diagnosis is established based on validated classification systems, most notably the Sydney criteria. These criteria mandate the coexistence of at least one clinical event (vascular thrombosis or defined pregnancy morbidity) and persistent laboratory evidence of antiphospholipid antibodies, including anticardiolipin antibodies, lupus anticoagulant, and/or anti–β2 glycoprotein I antibodies. Management primarily focuses on the prevention of recurrent thrombotic episodes through long-term anticoagulation therapy, typically using warfarin or heparin. In pregnant patients, a combination of low-dose aspirin and heparin is commonly administered to reduce the risk of miscarriage and other obstetric complications such as preeclampsia. Therapeutic decisions require careful balancing of thrombotic risk against potential bleeding complications, necessitating regular monitoring. The prognosis of APS depends on the extent and recurrence of thrombotic events, along with the presence of associated autoimmune conditions. Long-term care aims to minimize recurrent thrombosis, manage coexisting systemic diseases, and improve maternal and fetal outcomes. Owing to its multifaceted presentation and potential complications, APS requires coordinated multidisciplinary management and comprehensive patient education.